Helius Medical Technologies, Inc.

DB:26H Stock Report

Market Cap: €3.4m

Helius Medical Technologies Past Earnings Performance

Past criteria checks 0/6

Helius Medical Technologies has been growing earnings at an average annual rate of 10.2%, while the Medical Equipment industry saw earnings growing at 4.2% annually. Revenues have been declining at an average rate of 7.5% per year.

Key information

10.2%

Earnings growth rate

55.4%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate-7.5%
Return on equity-420.1%
Net Margin-1,602.4%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Helius Medical Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:26H Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 231-13103
30 Jun 231-10113
31 Mar 231-12113
31 Dec 221-14114
30 Sep 221-13115
30 Jun 221-17116
31 Mar 221-19136
31 Dec 211-18126
30 Sep 210-17125
30 Jun 210-15115
31 Mar 211-1395
31 Dec 201-14105
30 Sep 201-17115
30 Jun 201-19136
31 Mar 201-16157
31 Dec 191-10168
30 Sep 192-10169
30 Jun 192-8159
31 Mar 191-262010
31 Dec 180-291710
30 Sep 180-271611
30 Jun 180-361613
31 Mar 180-24914
31 Dec 170-28814
30 Sep 170-30814
30 Jun 170-20811
31 Mar 170-1888
31 Dec 160-1686
30 Sep 160-1274
30 Jun 160-763
31 Mar 160-764
31 Dec 150-554
30 Sep 150-554
30 Jun 150-1165
31 Mar 150-1055
31 Dec 140-843
30 Sep 140-632
30 Jun 140-311
31 Mar 140-110

Quality Earnings: 26H is currently unprofitable.

Growing Profit Margin: 26H is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 26H is unprofitable, but has reduced losses over the past 5 years at a rate of 10.2% per year.

Accelerating Growth: Unable to compare 26H's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 26H is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.3%).


Return on Equity

High ROE: 26H has a negative Return on Equity (-420.09%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/13 01:07
End of Day Share Price 2023/08/16 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Helius Medical Technologies, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anthony VendettiMaxim Group
Steven LichtmanOppenheimer & Co. Inc.
Andre UddinResearch Capital Corporation